Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
GC-3111 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
GC-3111: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
18F-92 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
18F-92: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
FF-10502 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
FF-10502: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
SK-NBP615 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SK-NBP615: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
VT-1092 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
VT-1092: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
S-525606 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
S-525606: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
MTX-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
MTX-101: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
NBI-1065890 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
NBI-1065890: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Pfs230D1-CRM197(Serum Institute of India) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Pfs230D1-CRM197(Serum Institute of India): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing.
8 min read
Human Antithrombin-III(Seoul National University Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Human Antithrombin-III(Seoul National University Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development.
8 min read
JPH-034 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
JPH-034: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
TOP-N53 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
TOP-N53: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.